Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption

M. H. Napimoga, E. P. Rocha, C. A. Trindade-da-Silva, A. P.D. Demasi, E. F. Martinez, C. G. Macedo, H. B. Abdalla, A. Bettaieb, Fawaz Haj, J. T. Clemente-Napimoga, B. Inceoglu, B. D. Hammock

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background and Objective: Soluble epoxide hydrolase (sEH) is an enzyme in the arachidonate cascade which converts epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 enzymes, to dihydroxy-eicosatrienoic acids. In the last 20 years with the development of inhibitors to sEH it has been possible to increase the levels of EETs and other EpFAs in in vivo models. Recently, studies have shown that EETs play a key role in blocking inflammation in a bone resorption process, but the mechanism is not clear. In the current study we used the sEH inhibitor (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea [TPPU]) to investigate the immunomodulatory effects in a mouse periodontitis model. Material and Methods: Mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 6) that were treated orally, daily for 15 days, with 1 mg/kg of TPPU. Then, the mice were killed and their jaws were analyzed for bone resorption using morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by microarray PCR or western blotting. Results: Infected mice treated with TPPU showed lower bone resorption than infected mice without treatment. Interestingly, infected mice showed increased expression of sEH; however, mice treated with TPPU had a reduction in expression of sEH. Besides, several proinflammatory cytokines and molecular markers were downregulated in the gingival tissue in the group treated with 1 mg/kg of TPPU. Conclusion: The sEH inhibitor, TPPU, showed immunomodulatory effects, decreasing bone resorption and inflammatory responses in a bone resorption mouse model.

Original languageEnglish (US)
Pages (from-to)743-749
Number of pages7
JournalJournal of Periodontal Research
Volume53
Issue number5
DOIs
StatePublished - Oct 1 2018

Fingerprint

Epoxide Hydrolases
Immunomodulation
Bone Resorption
Cytochrome P-450 Enzyme System
Fatty Acids
Aggregatibacter actinomycetemcomitans
Acids
Periodontitis
Jaw
Urea
Down-Regulation
Western Blotting
Cytokines
Inflammation
Polymerase Chain Reaction
Enzymes

Keywords

  • bone
  • epoxyeicosatrienoic acid
  • inflammation
  • periodontitis
  • soluble epoxide hydrolase
  • TPPU

ASJC Scopus subject areas

  • Periodontics

Cite this

Napimoga, M. H., Rocha, E. P., Trindade-da-Silva, C. A., Demasi, A. P. D., Martinez, E. F., Macedo, C. G., ... Hammock, B. D. (2018). Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. Journal of Periodontal Research, 53(5), 743-749. https://doi.org/10.1111/jre.12559

Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. / Napimoga, M. H.; Rocha, E. P.; Trindade-da-Silva, C. A.; Demasi, A. P.D.; Martinez, E. F.; Macedo, C. G.; Abdalla, H. B.; Bettaieb, A.; Haj, Fawaz; Clemente-Napimoga, J. T.; Inceoglu, B.; Hammock, B. D.

In: Journal of Periodontal Research, Vol. 53, No. 5, 01.10.2018, p. 743-749.

Research output: Contribution to journalArticle

Napimoga, MH, Rocha, EP, Trindade-da-Silva, CA, Demasi, APD, Martinez, EF, Macedo, CG, Abdalla, HB, Bettaieb, A, Haj, F, Clemente-Napimoga, JT, Inceoglu, B & Hammock, BD 2018, 'Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption', Journal of Periodontal Research, vol. 53, no. 5, pp. 743-749. https://doi.org/10.1111/jre.12559
Napimoga MH, Rocha EP, Trindade-da-Silva CA, Demasi APD, Martinez EF, Macedo CG et al. Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. Journal of Periodontal Research. 2018 Oct 1;53(5):743-749. https://doi.org/10.1111/jre.12559
Napimoga, M. H. ; Rocha, E. P. ; Trindade-da-Silva, C. A. ; Demasi, A. P.D. ; Martinez, E. F. ; Macedo, C. G. ; Abdalla, H. B. ; Bettaieb, A. ; Haj, Fawaz ; Clemente-Napimoga, J. T. ; Inceoglu, B. ; Hammock, B. D. / Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption. In: Journal of Periodontal Research. 2018 ; Vol. 53, No. 5. pp. 743-749.
@article{b7bbef08ea3c4b1f80c159dc13efae4f,
title = "Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption",
abstract = "Background and Objective: Soluble epoxide hydrolase (sEH) is an enzyme in the arachidonate cascade which converts epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 enzymes, to dihydroxy-eicosatrienoic acids. In the last 20 years with the development of inhibitors to sEH it has been possible to increase the levels of EETs and other EpFAs in in vivo models. Recently, studies have shown that EETs play a key role in blocking inflammation in a bone resorption process, but the mechanism is not clear. In the current study we used the sEH inhibitor (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea [TPPU]) to investigate the immunomodulatory effects in a mouse periodontitis model. Material and Methods: Mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 6) that were treated orally, daily for 15 days, with 1 mg/kg of TPPU. Then, the mice were killed and their jaws were analyzed for bone resorption using morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by microarray PCR or western blotting. Results: Infected mice treated with TPPU showed lower bone resorption than infected mice without treatment. Interestingly, infected mice showed increased expression of sEH; however, mice treated with TPPU had a reduction in expression of sEH. Besides, several proinflammatory cytokines and molecular markers were downregulated in the gingival tissue in the group treated with 1 mg/kg of TPPU. Conclusion: The sEH inhibitor, TPPU, showed immunomodulatory effects, decreasing bone resorption and inflammatory responses in a bone resorption mouse model.",
keywords = "bone, epoxyeicosatrienoic acid, inflammation, periodontitis, soluble epoxide hydrolase, TPPU",
author = "Napimoga, {M. H.} and Rocha, {E. P.} and Trindade-da-Silva, {C. A.} and Demasi, {A. P.D.} and Martinez, {E. F.} and Macedo, {C. G.} and Abdalla, {H. B.} and A. Bettaieb and Fawaz Haj and Clemente-Napimoga, {J. T.} and B. Inceoglu and Hammock, {B. D.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1111/jre.12559",
language = "English (US)",
volume = "53",
pages = "743--749",
journal = "Journal of Periodontal Research",
issn = "0022-3484",
publisher = "Blackwell Munksgaard",
number = "5",

}

TY - JOUR

T1 - Soluble epoxide hydrolase inhibitor promotes immunomodulation to inhibit bone resorption

AU - Napimoga, M. H.

AU - Rocha, E. P.

AU - Trindade-da-Silva, C. A.

AU - Demasi, A. P.D.

AU - Martinez, E. F.

AU - Macedo, C. G.

AU - Abdalla, H. B.

AU - Bettaieb, A.

AU - Haj, Fawaz

AU - Clemente-Napimoga, J. T.

AU - Inceoglu, B.

AU - Hammock, B. D.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Background and Objective: Soluble epoxide hydrolase (sEH) is an enzyme in the arachidonate cascade which converts epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 enzymes, to dihydroxy-eicosatrienoic acids. In the last 20 years with the development of inhibitors to sEH it has been possible to increase the levels of EETs and other EpFAs in in vivo models. Recently, studies have shown that EETs play a key role in blocking inflammation in a bone resorption process, but the mechanism is not clear. In the current study we used the sEH inhibitor (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea [TPPU]) to investigate the immunomodulatory effects in a mouse periodontitis model. Material and Methods: Mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 6) that were treated orally, daily for 15 days, with 1 mg/kg of TPPU. Then, the mice were killed and their jaws were analyzed for bone resorption using morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by microarray PCR or western blotting. Results: Infected mice treated with TPPU showed lower bone resorption than infected mice without treatment. Interestingly, infected mice showed increased expression of sEH; however, mice treated with TPPU had a reduction in expression of sEH. Besides, several proinflammatory cytokines and molecular markers were downregulated in the gingival tissue in the group treated with 1 mg/kg of TPPU. Conclusion: The sEH inhibitor, TPPU, showed immunomodulatory effects, decreasing bone resorption and inflammatory responses in a bone resorption mouse model.

AB - Background and Objective: Soluble epoxide hydrolase (sEH) is an enzyme in the arachidonate cascade which converts epoxy fatty acids (EpFAs), such as epoxyeicosatrienoic acids (EETs) produced by cytochrome P450 enzymes, to dihydroxy-eicosatrienoic acids. In the last 20 years with the development of inhibitors to sEH it has been possible to increase the levels of EETs and other EpFAs in in vivo models. Recently, studies have shown that EETs play a key role in blocking inflammation in a bone resorption process, but the mechanism is not clear. In the current study we used the sEH inhibitor (1-trifluoromethoxyphenyl-3-(1-propionylpiperidin-4-yl) urea [TPPU]) to investigate the immunomodulatory effects in a mouse periodontitis model. Material and Methods: Mice were infected on days 0, 2, and 4 with Aggregatibacter actinomycetemcomitans and divided into groups (n = 6) that were treated orally, daily for 15 days, with 1 mg/kg of TPPU. Then, the mice were killed and their jaws were analyzed for bone resorption using morphometry. Immunoinflammatory markers in the gingival tissue were analyzed by microarray PCR or western blotting. Results: Infected mice treated with TPPU showed lower bone resorption than infected mice without treatment. Interestingly, infected mice showed increased expression of sEH; however, mice treated with TPPU had a reduction in expression of sEH. Besides, several proinflammatory cytokines and molecular markers were downregulated in the gingival tissue in the group treated with 1 mg/kg of TPPU. Conclusion: The sEH inhibitor, TPPU, showed immunomodulatory effects, decreasing bone resorption and inflammatory responses in a bone resorption mouse model.

KW - bone

KW - epoxyeicosatrienoic acid

KW - inflammation

KW - periodontitis

KW - soluble epoxide hydrolase

KW - TPPU

UR - http://www.scopus.com/inward/record.url?scp=85047833712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85047833712&partnerID=8YFLogxK

U2 - 10.1111/jre.12559

DO - 10.1111/jre.12559

M3 - Article

C2 - 29851077

AN - SCOPUS:85047833712

VL - 53

SP - 743

EP - 749

JO - Journal of Periodontal Research

JF - Journal of Periodontal Research

SN - 0022-3484

IS - 5

ER -